Top Page
Sino Biopharmaceutical
(1177)
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Sino Biopharmaceutical Business Overview & Revenue Model
Sino Biopharmaceutical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.57B | 28.87B | 26.20B | 26.03B | 26.86B | 23.65B |
| Gross Profit | 24.99B | 23.53B | 21.21B | 21.54B | 21.53B | 18.46B |
| EBITDA | 6.11B | 6.11B | 6.98B | 6.69B | 19.87B | 5.66B |
| Net Income | 3.87B | 3.50B | 2.33B | 2.54B | 14.61B | 2.77B |
Balance Sheet | ||||||
| Total Assets | 74.89B | 65.41B | 63.60B | 64.06B | 60.54B | 47.21B |
| Cash, Cash Equivalents and Short-Term Investments | 19.82B | 14.60B | 14.12B | 16.92B | 15.79B | 16.43B |
| Total Debt | 11.96B | 9.78B | 12.58B | 13.98B | 12.12B | 14.21B |
| Total Liabilities | 29.12B | 22.63B | 25.43B | 26.12B | 22.81B | 24.79B |
| Stockholders Equity | 33.37B | 31.96B | 30.47B | 29.75B | 30.29B | 16.75B |
Cash Flow | ||||||
| Free Cash Flow | 2.89B | 5.22B | 4.36B | 4.56B | 3.47B | 3.47B |
| Operating Cash Flow | 3.16B | 6.62B | 6.07B | 6.27B | 5.37B | 5.33B |
| Investing Cash Flow | -7.29B | -1.71B | -756.98M | -4.07B | -2.52B | -7.85B |
| Financing Cash Flow | 1.58B | -6.32B | -6.55B | -3.19B | -3.23B | 2.23B |
Sino Biopharmaceutical Technical Analysis
Sino Biopharmaceutical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $141.38B | 31.20 | 9.79% | ― | 16.90% | 63.11% | |
68 Neutral | $72.78B | 27.98 | 15.34% | 0.84% | 7.51% | 44.09% | |
55 Neutral | $148.82B | 116.92 | 8.41% | ― | 52.78% | ― | |
54 Neutral | $124.66B | 31.23 | 11.72% | 1.29% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$102.43B | -109.23 | -14.40% | ― | 33.46% | -7.60% | |
43 Neutral | HK$39.44B | -25.46 | -15.06% | ― | 39.02% | 48.26% |
Sino Biopharmaceutical Corporate Events
Sino Biopharmaceutical has announced positive interim results from its Phase III clinical study of culmerciclib, a CDK2/4/6 inhibitor, in combination with fulvestrant for the first-line treatment of HR+/HER2-advanced breast cancer. The study, presented at the ESMO Congress 2025, demonstrated significant efficacy in delaying disease progression and improving response rates compared to the control group, with manageable safety profiles. These results position culmerciclib as a potential best-in-class therapy, enhancing the company’s standing in the oncology sector and offering promising implications for stakeholders.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its new drug, TQ-B3234, a selective MEK1/2 inhibitor, has been included in the Breakthrough Therapy Designation process by the Center for Drug Evaluation of China’s National Medical Products Administration. This inclusion is for the treatment of adult plexiform neurofibromas associated with neurofibromatosis type I, a condition with significant unmet medical needs in China. The drug has shown promising results in clinical trials, with high rates of tumor shrinkage and good tolerability, and its inclusion in the Breakthrough Therapy Designation process is expected to accelerate its launch, potentially benefiting more patients sooner.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its drug TQB2102, a HER2 bispecific antibody-drug conjugate, has been included in China’s Breakthrough Therapeutic Designation process. This inclusion is expected to expedite the drug’s approval, offering a promising treatment for HER2 IHC 3+ advanced colorectal cancer, a condition with limited effective treatment options. The drug has shown a 34.8% objective response rate in clinical trials, indicating significant potential to improve patient outcomes in a field where current therapies have limited efficacy.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in a Phase I clinical trial in Australia for its innovative drug, LM-350, a CDH17 antibody-drug conjugate developed by its subsidiary, LaNova Medicines. This marks a significant step in the clinical development of LM-350, which targets gastrointestinal tumors with high CDH17 expression, addressing unmet clinical needs in cancers such as colorectal, gastric, pancreatic, and esophageal. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of LM-350, with hopes of advancing treatment options for patients with advanced solid tumors.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in a Phase I clinical trial for LM-2417, a NaPi2b/4-1BB bispecific antibody, marking a significant step in its clinical development. This innovative therapy, developed by LaNova Medicines, targets NaPi2b, a promising anti-tumor target, and aims to enhance anti-tumor effects while minimizing toxicity. The trial will evaluate the safety and efficacy of LM-2417 as a monotherapy or in combination with other drugs, potentially positioning it as a First-in-Class immunotherapy.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its Investigational New Drug (IND) application for TQF3250, an innovative oral GLP-1 receptor agonist for type 2 diabetes, has been accepted by China’s National Medical Products Administration. The drug shows promising preclinical results, offering significant advantages in patient compliance and safety over existing injectable formulations. With the global GLP-1RA market expected to grow significantly, the acceptance of TQF3250 positions the company to potentially capture a share of this expanding market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced the approval of its zongertinib tablets, branded as Hernexeos®, for marketing in mainland China. This drug, developed in collaboration with Boehringer Ingelheim, is the first approved oral HER2 tyrosine kinase inhibitor for treating adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations. The approval is based on positive results from the Beamion-LUNG 1 study, showing high efficacy and a manageable safety profile. This development addresses significant unmet clinical needs in lung cancer treatment in China and enhances the company’s oncology product line.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced the presentation of data from four studies on their respiratory drugs at the 2025 European Respiratory Society Annual Meeting. The studies include TQC3721, a PDE3/4 inhibitor with bronchodilatory and anti-inflammatory effects, which has been granted Breakthrough Therapy Designation in China and is in Phase III trials. TQC2731, a TSLP monoclonal antibody, is progressing rapidly in trials for asthma and other inflammatory diseases. TQC3403, a combination of umeclidinium bromide and vilanterol, is set to become the first marketed generic version in China, expected by 2026. These developments highlight Sino Biopharmaceutical’s strong positioning in the respiratory drug market and potential impact on stakeholders.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its HER2-selective tyrosine kinase inhibitor, zongertinib, has been granted Breakthrough Therapeutic Designation by the Center for Drug Evaluation in China for treating unresectable or metastatic non-small cell lung cancer with HER2 mutations. This designation, supported by clinical trial results, highlights the potential of zongertinib to address the unmet need for targeted therapies in this patient population. The company’s strategic partnership with Boehringer Ingelheim aims to enhance cancer treatment options in China, leveraging both companies’ strengths to bring innovative oncology products to market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced that its innovative drug, LM-302 ‘CLDN18.2 ADC’, developed by its subsidiary LaNova Medicines, has been included in China’s Breakthrough Therapeutic Designation process. This drug, used in combination with a PD-1 monoclonal antibody, shows promise as a first-line therapy for certain advanced cancers. Recent clinical trials have demonstrated significant efficacy and manageable safety, with high response and disease control rates. The inclusion in the BTD process is expected to expedite the drug’s market availability, offering a new treatment option for patients with CLDN18.2-positive gastric cancer.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited is a leading pharmaceutical conglomerate in China, known for its innovative R&D-driven approach and a fully-integrated industrial chain that spans various therapeutic areas such as oncology, liver/metabolic diseases, respiratory, and surgery/analgesia. The company is listed on the Hong Kong Stock Exchange and has been recognized among the top global pharmaceutical enterprises.
Sino Biopharmaceutical Limited announced an interim cash dividend of HKD 0.05 per share for the financial year ending December 31, 2025. The ex-dividend date is set for August 29, 2025, with the payment date scheduled for September 23, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may enhance its attractiveness to investors.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical reported a significant financial performance for the first half of 2025, with a 10.7% increase in revenue to RMB 17.57 billion and a 140.2% rise in profit attributable to owners from continuing operations. This growth was driven by increased sales of innovative products and higher dividend income. The company’s strategic focus on innovative therapies and its robust market presence continue to strengthen its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3142, a novel PROTAC molecule targeting Bcl-xL protein for the treatment of malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug is designed to induce apoptosis in tumor cells with a reduced risk of platelet toxicity, offering a promising new treatment option in a field where no Bcl-xL inhibitors are currently approved worldwide.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3122, a PARP1 inhibitor designed for treating advanced malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug shows promise due to its high selectivity and ability to penetrate the blood-brain barrier, potentially offering new treatment options for intracranial tumors. The acceptance of this application marks a significant step for the company, as there are currently no approved drugs worldwide targeting the same mechanism, positioning Sino Biopharmaceutical as a potential leader in this niche market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced that its subsidiary, LaNova Medicines, has received approval from China’s National Medical Products Administration to conduct Phase II clinical trials for LM-24C5, a CEACAM5/4-1BB bispecific antibody. This innovative drug targets CEACAM5-positive advanced solid tumors and shows promise in enhancing anti-tumor activity by redirecting immune cells to the tumor microenvironment. The approval marks a significant step in the company’s efforts to develop a First-in-Class immunotherapy, potentially strengthening its position in the oncology treatment market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical announced that its independently developed Rovadicitinib Tablet, a JAK/ROCK inhibitor, has been included in the Breakthrough Therapeutic Designation process by China’s National Medical Products Administration for treating chronic graft-versus-host disease (cGVHD). This development marks a significant milestone as Rovadicitinib progresses through Phase III clinical trials in China and Phase II trials in the U.S., showcasing promising results in earlier trials with high response and survival rates. The company aims to expedite global R&D efforts to provide better treatment solutions for patients worldwide.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its new drug, TQC3302, a triple-combination soft mist inhalation formulation for chronic obstructive pulmonary disease (COPD), has received clinical trial approval from China’s National Medical Products Administration. This development marks a significant step in the company’s efforts to provide advanced treatment options for COPD patients, as no similar formulation has been approved globally, potentially enhancing the company’s market position and offering new opportunities for stakeholders.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced a board meeting scheduled for August 18, 2025, to approve the publication of its unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting could impact the company’s financial strategy and shareholder returns, reflecting its ongoing operational and financial planning.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its subsidiary, LaNova Medicines, is progressing smoothly with its out-licensing collaboration with Merck & Co., Inc. for the LM-299/MK-2010 PD-1/VEGF Bispecific Antibody. The company is set to receive a US$300 million milestone payment following the successful technology transfer. This collaboration, which grants Merck exclusive global rights for LM-299, includes an upfront payment of US$588 million and potential milestone payments up to US$2.7 billion, highlighting Sino Biopharmaceutical’s strategic positioning in the global pharmaceutical market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.